Cite
Mouritzen MT, Junker KF, Carus A, et al. Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study. Acta Oncol. 2022;1-8doi: 10.1080/0284186X.2021.2023213.
Mouritzen, M. T., Junker, K. F., Carus, A., Ladekarl, M., Meldgaard, P., Nielsen, A. W. M., Livbjerg, A., Larsen, J. W., Skuladottir, H., Kristiansen, C., Wedervang, K., Schytte, T., Hansen, K. H., Østby, A. C., Frank, M. S., Lauritsen, J., Sørensen, J. B., Langer, S. W., Persson, G. F., Andersen, J. L., Homann, P. H., Kristensen, E. B., Drivsholm, L. B., Bøgsted, M., Christensen, H. S., Pøhl, M., & Bjørnhart, B. (2022). Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study. Acta oncologica (Stockholm, Sweden), 1-8. https://doi.org/10.1080/0284186X.2021.2023213
Mouritzen, Mette T, et al. "Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study." Acta oncologica (Stockholm, Sweden) vol. (2022): 1-8. doi: https://doi.org/10.1080/0284186X.2021.2023213
Mouritzen MT, Junker KF, Carus A, Ladekarl M, Meldgaard P, Nielsen AWM, Livbjerg A, Larsen JW, Skuladottir H, Kristiansen C, Wedervang K, Schytte T, Hansen KH, Østby AC, Frank MS, Lauritsen J, Sørensen JB, Langer SW, Persson GF, Andersen JL, Homann PH, Kristensen EB, Drivsholm LB, Bøgsted M, Christensen HS, Pøhl M, Bjørnhart B. Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study. Acta Oncol. 2022 Jan 11;1-8. doi: 10.1080/0284186X.2021.2023213. Epub 2022 Jan 11. PMID: 35012430.
Copy
Download .nbib